Investigational AKT inhibitor AZD5363 is active against multiple tumor types with AKT1 E17K mutations
Treatment with the investigational pan-AKT inhibitor AZD5363 led to tumor regression in patients with a variety of types of solid tumors positive for the AKT1 E17K genetic mutation, according to data from a phase I clinical ...
Nov 9, 2015
0
3